Compare BVFL & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVFL | LUCD |
|---|---|---|
| Founded | 1873 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6M | 190.8M |
| IPO Year | 2023 | 2021 |
| Metric | BVFL | LUCD |
|---|---|---|
| Price | $19.40 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.94 |
| AVG Volume (30 Days) | 13.2K | ★ 493.4K |
| Earning Date | 01-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.19 | 16.67 |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | N/A | $126.14 |
| Revenue Next Year | N/A | $138.77 |
| P/E Ratio | $13.64 | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $13.65 | $0.95 |
| 52 Week High | $19.88 | $1.70 |
| Indicator | BVFL | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 31.77 |
| Support Level | $18.22 | $1.01 |
| Resistance Level | $19.81 | $1.14 |
| Average True Range (ATR) | 0.49 | 0.06 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 92.89 | 16.67 |
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.